News – Sound Bioventures

VarmX raises €30 million Series B2 financing for IND approvaland preparations for pivotal trial

Leiden, The Netherlands, 25 May 2023 – VarmX, a biotech company focusing on the development of innovative approaches for the reversal of anticoagulation, today announces it has successfully raised an additional €30 million in a Series B2 financing round. The round was led by Sound Bioventures whilst the European Innovation Council (EIC) Fund ...

Combining instinct & freedom to support startups

Casper Breum says he can usually tell early on if a startup will be a good fit for investment. As a founding partner at Sound Bioventures, Breum is involved in reviewing the roughly six hundred investor pitches from biotech companies the firm evaluates each year. His predictive ability was honed throughout his career, which he […]

We are excited to welcome Arthex to our portfolio

ARTHEx Biotech Announces Closing of €42 M Series B Financing to Advance ATX-01, its Novel Treatment for Myotonic Dystrophy Type 1 (DM1) The ArthemiRTM trial, a Phase I-IIa study of ATX-01 in DM1, is expected to initiate in 2H2023 Round led by Columbus Venture Partners, with participation of European Innovation Council (EIC), Hadean Ventures, Sound ...

Breye Therapeutics Strengthens Management Team and Board

“We are thrilled to welcome Peter as CSO. His extensive experience in ophthalmology drug development will be invaluable as we advance our lead compound through clinical development. Gabriela’s appointment to the Board brings significant industry and development experience which will be instrumental as we build a pipeline of novel oral therapies for ...

An ingrained efficiency to strengthen people & processes

Anne Marie Simon prefers to be backstage. There, from behind the scenes, she’s fearlessly dedicated to helping others shine. In her role as Office Manager for Sound Bioventures, for example, Simon is essential in optimizing the firm’s processes and supporting the investment team. From an early age, Simon knew she had a knack for working […] ...

The drive to adapt a lab discovery into treatment of neurodegeneration

Teitur Trophics is breaking new ground when it comes to neurodegenerative diseases. After identifying a previously unknown means of preserving functioning brain cells, the biotech company’s founders aim to translate that discovery into therapies for conditions with almost no current treatment options. According to Co-Founder and CEO Simon Mølgaard, ...

From toxin to remedy, and operating room to the boardroom

Even though it’s based on venom from one of the deadliest snakes in the world, the lead product of biotech startup VarmX can be life-saving for patients on blood thinners. It’s an unexpected turn, but those are the norm for the Dutch company’s Chairman and CEO, Dr. Jan Öhrström. His CV runs the gamut from […]

Teitur Trophics Raises EUR 28M in Series A Financing to Advance the Development and Treatment for Neurodegenerative Diseases

We are proud to support/co-lead @Teitur Trophics €28M Series A financing.

Building a legacy based on deep-rooted integrity

For Mukhopadhyay, the cornerstone of a future-proofed firm with a global reach is a leadership philosophy that embodies decency and humility.

A patient-centric mission for life-changing autoimmune treatments

Read about Artax Biopharma and their journey developing a revolutionary therapy for autoimmune diseases that makes a meaningful difference in patients lives.

A curiosity steeped in the business of science

Read about Ester Sklarsky and how her curiosity for life-science and innovation shaped a career in VC, permitting her to pursue the therapeutics of tomorrow and make a difference for patients.

A drive to help others and invest in people

Haul a portable ultrasound machine around the Amazon basin for a year, and you’ll learn a thing or two about yourself. For Philip Brainin, it was realizing he had a sincere and steadfast urge to help as many people as possible. And that would put Brainin on the path to his current position as Analyst […]